Carbetocin intranasal - Ferring Pharmaceuticals

Drug Profile

Carbetocin intranasal - Ferring Pharmaceuticals

Alternative Names: FE-992097; LV 101

Latest Information Update: 03 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ferring Pharmaceuticals
  • Class Oxytocics; Posterior pituitary hormones
  • Mechanism of Action Oxytocin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Prader-Willi syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase II Prader-Willi syndrome
  • Phase I Obesity

Most Recent Events

  • 21 Jun 2018 Final efficacy and safety data from a phase II trial in Prader-Willi syndrome released by Levo Therapeutics
  • 11 Aug 2017 Levo Therapeutics plans a pivotal phase III trial for Prader-Willi syndrome in 2018
  • 27 Oct 2016 Carbetocin intranasal licensed to Levo Therapeutics worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top